{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T15:17:40Z","timestamp":1783696660823,"version":"3.55.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100002794","name":"Swedish Cancer Society","doi-asserted-by":"publisher","award":["2013\/472"],"award-info":[{"award-number":["2013\/472"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NHMRC Early Career Fellowship","award":["1124210"],"award-info":[{"award-number":["1124210"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.eururo.2018.11.022","type":"journal-article","created":{"date-parts":[[2018,11,26]],"date-time":"2018-11-26T08:58:55Z","timestamp":1543222735000},"page":"676-683","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer"],"prefix":"10.1016","volume":"75","author":[{"given":"Kerri","family":"Beckmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Garmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Adolfsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Bosco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Holmberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Par","family":"Stattin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mieke","family":"Van Hemelrijck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2018.11.022_bib0120","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/bju.13026","article-title":"Non-steroidal antiandrogen monotherapy compared with luteinizing hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer: a Cochrane systematic review","volume":"116","author":"Kunath","year":"2015","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2018.11.022_bib0125","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/j.ejca.2014.03.279","article-title":"Patterns of androgen deprivation therapies among men diagnosed with localised prostate cancer: a population-based study","volume":"50","author":"Lycken","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eururo.2018.11.022_bib0130","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0090-4295(02)01576-5","article-title":"Antiandrogen monotherapy: indications and results","volume":"60","author":"Iversen","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2018.11.022_bib0135","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.clgc.2013.05.004","article-title":"Luteinizing hormone-releasing hormone agonists: a quick reference for prevalence rates of potential adverse effects","volume":"11","author":"Walker","year":"2013","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.eururo.2018.11.022_bib0140","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMoa041943","article-title":"Risk of fracture after androgen deprivation for prostate cancer","volume":"352","author":"Shahinian","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2018.11.022_bib0145","doi-asserted-by":"crossref","first-page":"7897","DOI":"10.1200\/JCO.2004.00.6908","article-title":"Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer","volume":"23","author":"Smith","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2018.11.022_bib0150","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/j.ejca.2012.01.035","article-title":"Incidence of fractures causing hospitalisation in prostate cancer patients: results from the population-based PCBaSe Sweden","volume":"48","author":"Thorstenson","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eururo.2018.11.022_bib0155","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.eururo.2014.11.039","article-title":"Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis","volume":"68","author":"Bosco","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2018.11.022_bib0160","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/jnci\/djp404","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer","volume":"102","author":"Keating","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2018.11.022_bib0165","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/ijc.26022","article-title":"Ischemic heart disease and stroke before and during endocrine treatment for prostate cancer in PCBaSe Sweden","volume":"130","author":"Robinson","year":"2012","journal-title":"Int J Cancer"},{"key":"10.1016\/j.eururo.2018.11.022_bib0170","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.1200\/JCO.2010.29.1567","article-title":"Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the Population-Based PCBaSe Sweden","volume":"28","author":"Van Hemelrijck","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2018.11.022_bib0175","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1200\/JCO.2014.59.1792","article-title":"Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer","volume":"33","author":"O\u2019Farrell","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2018.11.022_bib0180","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s12885-016-2221-5","article-title":"Stroke related to androgen deprivation therapy for prostate cancer: a meta-analysis and systematic review","volume":"16","author":"Meng","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.eururo.2018.11.022_bib0185","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/bju.13360","article-title":"Risk of thromboembolic disease in men with prostate cancer undergoing androgen deprivation therapy","volume":"118","author":"O\u2019Farrell","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2018.11.022_bib0190","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1200\/JCO.2006.05.9741","article-title":"Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy","volume":"24","author":"Braga-Basaria","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2018.11.022_bib0195","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1002\/ijc.30403","article-title":"Association between duration and type of androgen deprivation therapy and risk of diabetes in men with prostate cancer","volume":"139","author":"Crawley","year":"2016","journal-title":"Int J Cancer"},{"key":"10.1016\/j.eururo.2018.11.022_bib0200","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/pcan.2017.10","article-title":"Androgen deprivation therapy for prostate cancer and dementia risk: a systematic review and meta-analysis","volume":"20","author":"Nead","year":"2017","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.eururo.2018.11.022_bib0205","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1111\/j.1464-410X.2010.09319.x","article-title":"Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years","volume":"105","author":"Iversen","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2018.11.022_bib0210","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1093\/ije\/dys068","article-title":"Cohort Profile: the National Prostate Cancer Register of Sweden and Prostate Cancer data Base Sweden 2.0","volume":"42","author":"Van Hemelrijck","year":"2013","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.eururo.2018.11.022_bib0215","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"10.1016\/j.eururo.2018.11.022_bib0220","doi-asserted-by":"crossref","first-page":"e0117344","DOI":"10.1371\/journal.pone.0117344","article-title":"Quantifying the evidence for the risk of metabolic syndrome and its components following androgen deprivation therapy for prostate cancer: a meta-analysis","volume":"10","author":"Bosco","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.eururo.2018.11.022_bib0225","doi-asserted-by":"crossref","first-page":"e107516","DOI":"10.1371\/journal.pone.0107516","article-title":"Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies","volume":"9","author":"Zhao","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.eururo.2018.11.022_bib0230","doi-asserted-by":"crossref","unstructured":"Thomsen F, Bosco C, Garmo H, et al. Anti-androgen monotherapy versus gonadotropin-releasing hormone agonists in men with advanced, non-metastatic prostate cancer: a register-based, observational study. Acta Oncol. In press. https:\/\/doi.org\/10.1080\/0284186X.2018.1529427.","DOI":"10.1080\/0284186X.2018.1529427"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283818308790?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283818308790?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T08:38:45Z","timestamp":1565253525000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283818308790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S0302283818308790"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2018.11.022","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2018.11.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}